Miromatrix Medical Inc. announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance.

Mr. Douglas joins the Miromatrix team with over 25 years of relevant work experience in investment banking, industry, and public accounting. Since 2005, Jim worked at Piper Sandler in the healthcare investment banking group, advising biotechnology and medical technology companies on M&A and financing transactions, as well as providing a broad range of strategic guidance. At the time of his departure from Piper Sandler, Mr. Douglas was a managing director and the longest tenured investment banker on the biotechnology team.

Before Piper Sandler, Mr. Douglas worked at Abbott Laboratories in the corporate financial planning division and global pharmaceutical operations division (now AbbVie). Prior to Abbott, he worked at PricewaterhouseCoopers providing audit and transaction services. Mr. Douglas graduated from the University of Wisconsin–Milwaukee with an accounting degree and earned a Master of Business Administration degree specializing in analytical finance and marketing from the J.L. Kellogg School of Management at Northwestern University.

He is also a certified public accountant.